122 related articles for article (PubMed ID: 6112437)
1. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation.
Bartele V; Cerletti C; Schiepatti A; di Minno G; de Gaetano G
Lancet; 1981 May; 1(8228):1057-8. PubMed ID: 6112437
[No Abstract] [Full Text] [Related]
2. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G
Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411
[No Abstract] [Full Text] [Related]
3. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
Lancet; 1982 Nov; 2(8308):1156-7. PubMed ID: 6128469
[No Abstract] [Full Text] [Related]
4. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane synthase inhibition in patients with atherosclerotic heart disease.
Knudsen JB; Juhl A; Gormsen J
Lancet; 1981 Jul; 2(8239):198. PubMed ID: 6114260
[No Abstract] [Full Text] [Related]
6. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
Cerletti C; Rajtar G; Bertelé V; de Gaetano G
Thromb Haemost; 1984 Oct; 52(2):215. PubMed ID: 6441306
[No Abstract] [Full Text] [Related]
7. Biology and biochemistry of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
[No Abstract] [Full Text] [Related]
8. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
Randall MJ; Parry MJ; Hawkeswood E; Cross PE; Dickinson RP
Thromb Res; 1981 Jul 1-15; 23(1-2):145-62. PubMed ID: 6795753
[No Abstract] [Full Text] [Related]
9. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
[TBL] [Abstract][Full Text] [Related]
10. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G
Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245
[TBL] [Abstract][Full Text] [Related]
11. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
12. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
Varfolomeev SD; Lakin KM; Mevkh AT; Novikova NV; Rukazenkov IuZ
Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305
[No Abstract] [Full Text] [Related]
13. Effect of the thromboxane synthetase inhibitor Dazoxiben (UK 37-248) on the metabolism of antipyrine in patients with enhanced platelet aggregation.
Staiger C; Walter E; Wang NS; Schuhmacher E; de Vries J; Weber E
Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):250-3. PubMed ID: 6540249
[TBL] [Abstract][Full Text] [Related]
14. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
Lecompte T; Joussemet M; Hainaut J
Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
[No Abstract] [Full Text] [Related]
15. Influence of a thromboxane synthesis inhibitor on the muscle tissue microcirculation of patients with intermittent claudication.
Ehrly AM
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):117S-118S. PubMed ID: 6681700
[No Abstract] [Full Text] [Related]
16. Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase.
Smith JB
Thromb Res; 1982 Nov; 28(4):477-85. PubMed ID: 6891843
[TBL] [Abstract][Full Text] [Related]
17. Lack of synergism between dazoxiben and dipyridamole following administration to man.
Gresele P; Deckmyn H; Arnout J; Zoja C; Vermylen J
Thromb Res; 1985 Jan; 37(1):231-6. PubMed ID: 3838601
[No Abstract] [Full Text] [Related]
18. Thromboxane synthetase inhibition as antithrombotic strategy.
Vermylen J; Defreyn G; Carreras LO; Machin SJ; Van Schaeren J; Verstraete M
Lancet; 1981 May; 1(8229):1073-5. PubMed ID: 6112447
[TBL] [Abstract][Full Text] [Related]
19. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation.
Butler KD; Maguire ED; Smith JR; Turnbull AA; Wallis RB; White AM
Thromb Haemost; 1982 Feb; 47(1):46-9. PubMed ID: 6461944
[TBL] [Abstract][Full Text] [Related]
20. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
Schumacher WA; Lucchesi BR
J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
